Syntara Ltd (SNT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.694x

Based on the latest financial reports, Syntara Ltd (SNT) has a cash flow conversion efficiency ratio of -0.694x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-11.12 Million ≈ $-7.86 Million USD) by net assets (AU$16.02 Million ≈ $11.33 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Syntara Ltd - Cash Flow Conversion Efficiency Trend (2004–2023)

This chart illustrates how Syntara Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Syntara Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Syntara Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Syntara Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Curo Holdings Co. Ltd
KQ:051780
-0.068x
Santierul Naval Orsova SA
RO:SNO
0.014x
Projektengagemang Sweden AB (publ)
ST:PENG-B
0.038x
EasyJet PLC
LSE:EZJ
0.265x
SWISS PROPERTIES INV.100
F:SR1
N/A
Fridenson
TA:FRDN
0.055x
Hulamin
JSE:HLM
0.009x
Zanaga Iron Ore Company Limited
F:6ZA
0.001x

Annual Cash Flow Conversion Efficiency for Syntara Ltd (2004–2023)

The table below shows the annual cash flow conversion efficiency of Syntara Ltd from 2004 to 2023. For the full company profile with market capitalisation and key ratios, see Syntara Ltd (SNT) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2023-06-30 AU$9.56 Million
≈ $6.76 Million
AU$-7.28 Million
≈ $-5.15 Million
-0.761x +49.55%
2022-06-30 AU$10.80 Million
≈ $7.64 Million
AU$-16.30 Million
≈ $-11.54 Million
-1.509x -239.75%
2021-06-30 AU$2.85 Million
≈ $2.01 Million
AU$3.07 Million
≈ $2.17 Million
1.080x +111.63%
2020-06-30 AU$1.43 Million
≈ $1.01 Million
AU$-13.28 Million
≈ $-9.40 Million
-9.283x -594.61%
2019-06-30 AU$14.81 Million
≈ $10.48 Million
AU$-19.80 Million
≈ $-14.01 Million
-1.336x -221.73%
2018-06-30 AU$11.12 Million
≈ $7.87 Million
AU$12.21 Million
≈ $8.64 Million
1.098x +125.33%
2017-06-30 AU$3.52 Million
≈ $2.49 Million
AU$-15.26 Million
≈ $-10.80 Million
-4.335x -656.57%
2016-06-30 AU$20.93 Million
≈ $14.81 Million
AU$-11.99 Million
≈ $-8.48 Million
-0.573x -195.54%
2015-06-30 AU$36.32 Million
≈ $25.70 Million
AU$21.78 Million
≈ $15.41 Million
0.600x +138.51%
2014-06-30 AU$18.07 Million
≈ $12.78 Million
AU$-28.13 Million
≈ $-19.91 Million
-1.557x -198.78%
2013-06-30 AU$67.89 Million
≈ $48.04 Million
AU$-35.38 Million
≈ $-25.04 Million
-0.521x -50.03%
2012-06-30 AU$109.80 Million
≈ $77.69 Million
AU$-38.14 Million
≈ $-26.99 Million
-0.347x +34.15%
2011-06-30 AU$70.83 Million
≈ $50.12 Million
AU$-37.37 Million
≈ $-26.44 Million
-0.528x -52.90%
2010-06-30 AU$115.02 Million
≈ $81.38 Million
AU$-39.68 Million
≈ $-28.08 Million
-0.345x -79.48%
2009-06-30 AU$137.69 Million
≈ $97.43 Million
AU$-26.47 Million
≈ $-18.73 Million
-0.192x -21.48%
2008-06-30 AU$119.12 Million
≈ $84.29 Million
AU$-18.85 Million
≈ $-13.34 Million
-0.158x +41.47%
2007-06-30 AU$76.56 Million
≈ $54.17 Million
AU$-20.70 Million
≈ $-14.64 Million
-0.270x -94.07%
2006-06-30 AU$98.89 Million
≈ $69.97 Million
AU$-13.78 Million
≈ $-9.75 Million
-0.139x +46.58%
2005-06-30 AU$35.57 Million
≈ $25.17 Million
AU$-9.27 Million
≈ $-6.56 Million
-0.261x -50.10%
2004-06-30 AU$26.78 Million
≈ $18.95 Million
AU$-4.65 Million
≈ $-3.29 Million
-0.174x --

About Syntara Ltd

AU:SNT Australia Drug Manufacturers - Specialty & Generic
Market Cap
$31.20 Million
AU$44.09 Million AUD
Market Cap Rank
#23581 Global
#939 in Australia
Share Price
AU$0.03
Change (1 day)
-3.57%
52-Week Range
AU$0.02 - AU$0.07
All Time High
AU$0.40
About

Syntara Limited operates as a clinical-stage drug development company that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate, amsulostat, is being developed for the treatment of bone marrow cancer myelofibrosis and i… Read more